Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ICCC vs CSBR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ICCC Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

ICCC Overall Winner 6-Pillar Tally: ICCC 3 – 2 CSBR (1 Tie) Matrix Metrics: ICCC 6 – 4 CSBR

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas CSBR carries 44.4/100 (HOLD) at $4.68 (46.8x Forward P/E, -1.5% operating margin).

  • Composite vs. Pillar Nuance: While CSBR currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. -1.5% operating margin) and revenue trajectory (+11.5% vs. +8.8% YoY).
  • Technical & Structure Timing Caution: ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ICCC vs CSBR
ICCC NASDAQ Head-to-Head Winner
Immucell Corp
In Vitro & In Vivo Diagnostic Substances
$11.42
+6.23% 1D
Market Cap $97.7M
TTM Revenue $67M
Forward P/E N/M
Beta / 30D Vol 0.24β · 46% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 15.0 Fund 48.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.9% over 20 days), RSI 68
RSI-14: 67.5 · SMA20: $10.37 · SMA50: $10.13
CSBR NASDAQ
Champions Oncology, Inc.
Biological Products, (No Disgnostic Substances)
$4.68
-0.53% 1D
Market Cap $65.5M
TTM Revenue $61M
Forward P/E 46.8x
Beta / 30D Vol 0.36β · 24% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 46.0 Fund 49.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.0%), weak momentum, RSI 42
RSI-14: 42.2 · SMA20: $4.79 · SMA50: $4.89

6-Pillar Scorecard Institutional Category Breakdown (ICCC 3 – 2 CSBR)

Columns: Metric · ICCC · CSBR
1. Valuation Multiples CSBR
Forward P/E N/M 46.8x
Trailing P/E 56.6x 22.9x
PEG Ratio N/M N/M
EV / Revenue 1.6x 1.1x
2. Growth & Scale ICCC
Revenue Growth (YoY) +11.5% +8.8%
Earnings Growth (YoY) +259.9% -61.1%
TTM Revenue (USD) $67M $61M
Market Cap $97.7M $65.5M
3. Profitability & Quality ICCC
Gross Margin 40.3% 49.8%
Operating Margin 15.2% -1.5%
Net Profit Margin 2.6% -1.9%
Return on Equity (ROE) 2.6% -28.4%
4. Balance Sheet & Cash Flow ICCC
Cash Generation (TTM) $7.4M $402,000 EBITDA
Cash Flow Margin 11.0% 0.7% EBITDA Mgn
Net Cash / Leverage $13M Net Debt (0.44x D/E) $0.28 Book/Sh · -28.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat CSBR
OpEx & R&D Intensity 25.1% of Rev ($17M) 51.3% of Rev ($31M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ICCC (6) vs CSBR (4)
Institutional Metric ICCC CSBR Criterion Row Edge
Market Capitalization
Scale
$97.7M $65.5M Larger Scale ICCC
Trailing P/E Ratio
Valuation
56.6x 22.9x Lower Multiple CSBR
Forward P/E Ratio
Valuation
N/M 46.8x Lower Multiple CSBR
Revenue Growth (YoY)
Growth
+11.5% +8.8% Higher Growth ICCC
Operating Margin (TTM)
Profitability
15.2% -1.5% Higher Margin ICCC
Net Profit Margin
Profitability
2.6% -1.9% Higher Margin ICCC
Return on Equity (ROE)
Capital Efficiency
2.6% -28.4% Higher ROE ICCC
52-Week Range Position
Momentum
91% ($5–$12) 4% ($5–$8) Stronger Trend ICCC
Beta / 30D Volatility
Risk Regime
0.24β · 46% Vol 0.36β · 24% Vol Lower Realized Risk CSBR
Unified Institutional Score
Composite Signal
43.8 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite CSBR
Trailing 12M Revenue (USD)
Operating Scale
$67M $61M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
40.3% 49.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.6x EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.4M ($13M Net Debt (0.44x D/E)) $402,000 EBITDA ($0.28 Book/Sh · -28.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ICCC +6.66 pp
ICCC: +6.23% · CSBR: -0.43%
3M Horizon ICCC +25.07 pp
ICCC: +17.01% · CSBR: -8.06%
6M Horizon ICCC +38.14 pp
ICCC: +15.24% · CSBR: -22.9%
1Y Horizon ICCC +120.93 pp
ICCC: +88.76% · CSBR: -32.17%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ICCC vs CSBR. Trailing 12-month operating profitability (ICCC 15.2% vs CSBR -1.5%) and valuation multiples (ICCC N/M vs CSBR 46.8x Forward P/E) are benchmarked directly in Pillar 4 below.

ICCC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$67M
Gross Margin40.3%
Op. Margin15.2%
ROE / Fwd P/E2.6% · N/M
CSBR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$61M
Gross Margin49.8%
Op. Margin-1.5%
ROE / Fwd P/E-28.4% · 46.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ICCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ICCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CSBR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CSBR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ICCC Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment 25.1% of Rev ($17M)
90D Engineering Disclosures 0 Published
CSBR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.5M market capitalization and -1.5% operating margin.
OpEx & R&D Reinvestment 51.3% of Rev ($31M)
90D Engineering Disclosures 0 Published

Investor FAQ ICCC vs CSBR Key Questions & Quantitative Answers

As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Champions Oncology, Inc. (CSBR) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ICCC carries a Unified Composite Score of 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin), whereas CSBR carries 44.4/100 (HOLD) at $4.68 (46.8x Forward P/E, -1.5% operating margin). Composite vs. Pillar Nuance: While CSBR currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. ICCC 43.8/100 HOLD), ICCC captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (15.2% vs. -1.5% operating margin) and revenue trajectory (+11.5% vs. +8.8% YoY). Technical & Structure Timing Caution: ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5); meanwhile CSBR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ICCC leads the Growth & Scale pillar: ICCC posts +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin), compared with CSBR at +8.8% YoY revenue growth and -61.1% YoY earnings growth on $61M TTM revenue (49.8% gross margin, -1.5% operating margin). On trailing 12-month operating scale, ICCC generates $67M in USD-normalized revenue versus $61M for CSBR. In operating R&D and SG&A reinvestment, ICCC deploys 25.1% of Rev ($17M) (0 90-day corporate R&D disclosures) versus 51.3% of Rev ($31M) (0 disclosures) for CSBR.

CSBR screens cheaper on headline valuation multiples. ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin), whereas CSBR trades at 46.8x Forward P/E, 22.9x Trailing P/E, N/M PEG, and 1.1x EV/Revenue (0.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ICCC (2.6% ROE) versus CSBR (-28.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk). By comparison, CSBR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.36β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.